Literature DB >> 6108078

The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs.

D J Luchins, W J Freed, R J Wyatt.   

Abstract

From a review of the clinical literature, the authors determined that the medical symptoms of neuroleptic withdrawal occurred more frequently with neuroleptics having potent anticholinergic effects than with those having weak anticholinergic actions. When antiparkinsonian agents were not simultaneously withdrawn, there was a striking difference between these two categories of neuroleptics. Experiments with mice showed that withdrawal of haloperidol, a neuroleptic with weak anticholinergic effects, produced subsensitivity (depression of locomotor activity and seizure thresholds) to the cholinergic effects of physostigmine. These findings support the theory that the medical side effects of neuroleptic withdrawal are due to rebound cholinergic hypersensitivity associated with the anticholinergic actions of these drugs, rather than being related to their dopamine-blocking activity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108078     DOI: 10.1176/ajp.137.11.1395

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

Review 1.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

3.  Rebound insomnia after abrupt clozapine withdrawal.

Authors:  J Staedt; G Stoppe; G Hajak; E Ruther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 4.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

5.  Withdrawal akinesia.

Authors:  F Inoue; A M Janikowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-10       Impact factor: 10.154

6.  Symptoms of withdrawal from tricyclic antidepressants.

Authors:  M O Agbayewa
Journal:  Can Med Assoc J       Date:  1981-09-01       Impact factor: 8.262

Review 7.  Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Authors:  K Black; C Shea; S Dursun; S Kutcher
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

8.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

9.  A depot neuroleptic withdrawal study neurological effects.

Authors:  B Wistedt; D Wiles; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation-Is It Feasible to Develop Evidence-Based Guidelines?

Authors:  Graham Blackman; Ebenezer Oloyede; Mark Horowitz; Robert Harland; David Taylor; James MacCabe; Philip McGuire
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 9.306

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.